Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Teradyne, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.93 (market cap $29.60B), while Teradyne, Inc. trades at $404.66 (market cap $59.34B). The key difference: Teradyne, Inc. is far larger — about 2× Alnylam Pharmaceuticals, Inc.'s market cap, and Teradyne, Inc. pays a 0.14% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TER | |
|---|---|---|
Market Cap | $29.60B | $59.34B |
Sector | Health | Technology |
52-Week High | $491.22 | $483.84 |
52-Week Low | $205.48 | $109.30 |
Enterprise Value | $27.56B | $59.09B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Teradyne (TER) trades at $403.6, up 10.55% in 24 hours, near its 52-week high. The stock exhibits bullish technical signals with strong earnings beats in recent quarters, including Q2 2026 EPS of $2.47 versus $2.09 expected. Revenue growth is accelerating, driven by AI-led demand in semiconductor testing and robotics, with 2026 revenue projected at $4.5 billion. Valuation ratios are elevated, with a P/E of 52.14, reflecting high growth expectations.
The outlook remains positive due to robust AI-driven demand and record earnings, though high valuation poses a risk if growth slows. Analyst consensus is strongly bullish with a $481.63 price target. Key risks include execution challenges in scaling operations and sensitivity to semiconductor cycle downturns. Institutional buying, such as Anson Funds' purchase in Q1 2026, supports momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
